LONDON -(Dow Jones)- The cost regulator for the U.K.'s publicly funded National Health Service Thursday recommended use of Merck & Co. Inc.'s (MRK) injectable anti-inflammatory drug Simponi after the U.S.-based manufacturer provided more information about the product.
